浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Literature analysis of adverse drug reactions induced by dronedarone
- ZHONGGUO YAOFANG Vol. 34, Issue 7, Pages: 854-858(2023)
- 作者机构：
1.天津医科大学第二医院药学部，天津 300202
2.天津医科大学肿瘤医院乳腺外科，天津 300202
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.07.16
CLC： R972+.2Published：15 April 2023，
Received：24 October 2022，
Revised：27 March 2023，
扫 描 看 全 文
上官可可,曹曼卿,王荣环.决奈达隆的药物不良反应文献分析 Δ[J].中国药房,2023,34(07):854-858.
SHANGGUAN Keke,CAO Manqing,WANG Ronghuan.Literature analysis of adverse drug reactions induced by dronedarone[J].ZHONGGUO YAOFANG,2023,34(07):854-858.
上官可可,曹曼卿,王荣环.决奈达隆的药物不良反应文献分析 Δ[J].中国药房,2023,34(07):854-858. DOI： 10.6039/j.issn.1001-0408.2023.07.16.
SHANGGUAN Keke,CAO Manqing,WANG Ronghuan.Literature analysis of adverse drug reactions induced by dronedarone[J].ZHONGGUO YAOFANG,2023,34(07):854-858. DOI： 10.6039/j.issn.1001-0408.2023.07.16.
摘要
目的
2
分析决奈达隆药物不良反应（ADR）的临床表现及特点，为临床安全用药提供参考。
方法
2
计算机检索PubMed数据库、万方数据、中国知网、维普网自建库起至2022年8月31日收录的决奈达隆ADR的案例报道，对案例中患者年龄、性别、国籍，决奈达隆的用法用量，ADR发生的时间分布、临床表现、治疗措施及转归情况等进行回顾性分析。
结果
2
共纳入案例报道26篇，合计27例患者。患者年龄41～86岁，平均年龄为68.8岁，其中60～79岁年龄段发生ADR较多（20例，74.1％）。男性（14例）与女性（13例）数量相差不大。患者来源于6个国家，美国最多（16例，59.3％）。14例患者用法用量为400 mg，bid；1例为200 mg，bid；12例患者未明确用法用量。用药1个月内ADR发生率较高（16例，59.3%），其中11例发生于1周内（40.7%），无用药12个月以上的ADR报道。ADR累及系统器官以肝胆疾病（7例次，23.3％），皮肤和皮下组织疾病（6例次，20.0%），呼吸道、胸膈和纵隔疾病（5例次，16.7%）为主，此外还包括心脏疾病、肾脏和泌尿系统疾病、血管病、医学检查、眼部疾病。27例患者中，3例发生死亡，其不良反应分别为闭塞性细支气管炎伴机化性肺炎、中毒性表皮坏死松解症、肝功能衰竭；1例进行了肝移植。
结论
2
决奈达隆存在多器官系统的ADR，用药前需完善包括心电图、肝功能、肺功能等检查；用药1个月内应加强用药监测，尤其是肝胆、皮肤、呼吸道系统的ADR。其严重ADR的发生与用药时间长短无明显关系，需要持续进行药学监护和随访，以确保患者临床用药安全。
Abstract
OBJECTIVE
2
To analyze the clinical manifestations and characteristics of adverse drug reactions （ADR） induced by dronedarone，and to provide reference for clinically safe drug use.
METHODS
2
Retrieved from PubMed database， Wanfang database，CNKI and VIP （up to August 31st， 2022），ADR cases of dronedarone were analyzed retrospectively in respect of patient’s age，gender，nationality，usage and dosage of dronedarone，and occurrence time，clinical manifestations，treatment measures and outcome of ADR，etc.
RESULTS
2
A total of 26 case reports were included，with a total of 27 patients. The age of the patients was 41-86 years old，with an average age of 68.8 years. The proportion of patients aged 60-79 was the largest （20 cases，74.1%）. There was no significant difference in the number of males （14 cases） and females （13 cases）. The patients came from 6 countries，of which the United States was the largest （16 cases，59.3%）. The dosage of 14 patients was 400 mg bid；one patient was 200 mg bid；the dosage for 12 patients was not specified. The most ADR cases （16 cases，59.3%） occurred within 1 month，of which 11 cases（40.7%） occurred within 1 week，and there were no ADR reports with medication more than 12 months. Organs/systems involved in ADRs were mainly liver and biliary diseases （7 case times，23.3%），skin and subcutaneous tissue diseases （6 case times，20.0%），respiratory tract，thoracic and mediastinal diseases （5 case times，16.7%）. In addition，ADR also occurred in heart diseases，kidney and urinary system diseases，vascular diseases，medical examinations and eye diseases. Among 27 patients，there were 3 cases of death，the ADR were bronchiolitis obliterans with organizing pneumonia，toxic epidermal necrolysis and hepatic failure，respectively. One patient underwent liver transplantation.
CONCLUSIONS
2
Dronedarone can cause multiple organ system ADR. Before use，it is necessary to improve the examination including ECG，liver function，lung function，etc. and strengthen drug use monitoring within one month after the start of use，especially the ADR of hepatobiliary，skin and respiratory system. The occurrence of severe ADR has no obvious relationship with the duration of medication； even if it is taken safely for a long time，it still needs continuous pharmaceutical monitoring and follow-up to ensure the clinical medication safety of patients.
关键词
决奈达隆不良反应文献分析闭塞性细支气管炎伴机化性肺炎中毒性表皮坏死松解症肝功能衰竭
Keywords
adverse drug reactionliterature analysisbronchiolitis obliterans with organizing pneumoniatoxic epidermal necrolysishepatic failure
references
中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，中国房颤中心联盟心房颤动防治专家工作委员会，等. 心房颤动：目前的认识和治疗建议：2021[J]. 中华心律失常学杂志，2022，26（1）：15-88.
HOHNLOSER S H，CRIJNS H J，VAN EICKELS M，et al. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med，2009，360（7）：668-678.
GUZMÁN RAMOS M I，ROMERO GARCÍA T，MÁRQUEZ SAAVEDRA E，et al. Dronedarone-induced liver injury：a case report[J]. Gastroenterol Hepatol，2018，41（10）：636-638.
RUIZ J J D P，MARTÍN S A，ALVAREZ V G，et al. Hepatotoxicidad asociada al uso de dronedarona. A propósito de un caso[J]. Farma Hosp，2012，36（6）：545-547.
JAHN S，ZOLLNER G，LACKNER C，et al. Severe toxic hepatitis associated with dronedarone[J]. Curr Drug Saf，2013，8（3）：201-202.
JOGHETAEI N，WEIRICH G，HUBER W，et al. Acute liver failure associated with dronedarone[J]. Circ Arrhythm Electrophysiol，2011，4（4）：592-593.
MALAS H，ATTAR D，LOREE S，et al. Dronedarone leading to acute liver failure and rapid recovery：a case report[J]. J Am Coll Cardiol，2018，71（11）：A2568.
KHAN Z H，MUKHTAR K，AHMED M M，et al. Dronedarone-mediated acute hepatic and renal toxicity[J]. Cureus，2020，12（8）：e9611.
THORNTON D，AVERY S，EDEY A J，et al. Organising pneumonia due to dronedarone[J]. J R Coll Physicians Edinb，2015，45（3）：213-214.
STACK S，NGUYEN D V，CASTO A，et al. Diffuse alveolar damage in a patient receiving dronedarone[J]. Chest，2015，147（4）：e131-e133.
SIU C W，WONG M P，HO C M，et al. Fatal lung toxic effects related to dronedarone use[J]. Arch Intern Med，2012，172（6）：516-517.
HERNÁNDEZ VOTH A R，CATALÁN J S，BENAVIDES MAÑAS P D，et al. A 73-year-old man with interstitial lung disease due to dronedarone[J]. Am J Respir Crit Care Med，2012，186（2）：201-202.
AMAR L，KHALIL M，SHULMAN K，et al. Dronedarone- induced photoallergic reaction[J]. JAAD Case Rep，2020，6（12）：1208-1210.
DATAR P，KAFLE P，SCHMIDT F M，et al. Dronedarone- induced phototoxicity in a patient with atrial fibrillation[J]. Cureus，2019，11（9）：e5731.
LADIZINSKI B，ELPERN D J. Dronaderone-induced phototoxicity[J]. J Drugs Dermatol，2013，12（8）：946-947.
AL-JARRAH R，BLASINI A，KURGYIS Z，et al. Severe photoallergy to systemic dronedarone （multaq）[J]. Contact Dermatitis，2020，83（3）：241-242.
MIQUEL J，ADAMSKI H，OGER E，et al. Febrile maculopapular eruption due to dronedarone[J]. Ann Dermatol Venereol，2012，139（11）：740-742.
GECKS T，PROCHNAU D，FRANZ M，et al. Toxic epidermal necrolysis during dronedarone treatment：first report of a severe serious adverse event of a new antiarrhythmic drug[J]. Cardiovasc Toxicol，2015，15（4）：399-401.
YOUNG C，MARUTHAPPU M，WAYNE R P，et al. Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy[J]. J R Coll Physicians Edinb，2013，43（2）：122-125.
HUEMER M，SARGANAS G，BRONDER E，et al. Tor- sade de pointes tachycardia in a patient on dronedarone therapy[J]. Pharmacotherapy，2015，35（5）：e61-e65.
ROSMAN J，HOFFMEISTER P，REYNOLDS M，et al. Possible proarrhythmia with dronedarone[J]. J Cardiovasc Electrophysiol，2013，24（1）：103-104.
GONZALEZ J E，SAUER W H，KRANTZ M J. Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy[J]. Pharmacotherapy，2013，33（10）：e179-e181.
COONS J C，PLAUGER K M，SEYBERT A L，et al. Worsening heart failure in the setting of dronedarone initiation[J]. Ann Pharmacother，2010，44（9）：1496-1500.
HASSIB M，ELKHOULY A，ANSARI S，et al. A case of dronedarone-induced hypotensive shock[J]. Cureus，2020，12（6）：e8478.
SMITH S M，AL-BATAINEH M，IORFIDO S B，et al. A case report：multaq-induced leukocytoclastic vasculitis[J]. Am J Ther，2014，21（3）：e69-e70.
SELVARAJ V，JOHNSON K G. Dronedarone-induced optic neuropathy[J]. Int J Cardiol，2013，167（1）：e8-e9.
RAGUCCI K R. Elevated liver enzymes associated with dronedarone for atrial fibrillation[J]. SAGE Open Med Case Rep，2013，1：2050313X13511600.
GENZ C，ESPERER H D，SCHMEISSER A，et al. Marked prolongation of QRS duration after initiation of dronedarone therapy[J]. Heart Int，2014，9（1）：33-35.
HOY S M，KEAM S J. Dronedarone[J]. Drugs，2009，69（12）：1647-1663.
FROMENTY B，FISCH C，LABBE G，et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice[J]. J Pharmacol Exp Ther，1990，255（3）：1371-1376.
盛海燕，冯瑞娥，胥杰，等. 胺碘酮肺部不良反应二例[J]. 中华结核和呼吸杂志，2020，43（11）：977-980.
QUAGLINO D，HA H R，DUNER E，et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages：structure-activity relationship[J]. Am J Physiol Lung Cell Mol Physiol，2004，287（2）：L438-L447.
SINGH B N，CONNOLLY S J，CRIJNS H J，et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med，2007，357（10）：987-999.
0
Views
14
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.